These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21913404)

  • 1. [Characteristics of ertapenem use in critical state patients].
    Beloborodov VB
    Antibiot Khimioter; 2011; 56(3-4):10-2, 14-6. PubMed ID: 21913404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
    Hammond ML
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii7-9. PubMed ID: 15150178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion of ertapenem into bone and synovial tissues.
    Boselli E; Breilh D; Djabarouti S; Bel JC; Saux MC; Allaouchiche B
    J Antimicrob Chemother; 2007 Oct; 60(4):893-6. PubMed ID: 17704514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
    Loza E; Morosini MI; Cantón R; Almaraz F; Reig M; Baquero F
    Rev Esp Quimioter; 2003 Jun; 16(2):209-15. PubMed ID: 12973459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of ertapenem.
    Teppler H; Gesser RM; Friedland IR; Woods GL; Meibohm A; Herman G; Mistry G; Isaacs R
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii75-81. PubMed ID: 15150186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infection after elective colorectal surgery: bacteriological analysis of failures in a randomized trial of cefotetan vs. ertapenem prophylaxis.
    Goldstein EJ; Citron DM; Merriam CV; Abramson MA
    Surg Infect (Larchmt); 2009 Apr; 10(2):111-8. PubMed ID: 19226203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
    Goldstein EJ; Snydman DR
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii29-36. PubMed ID: 15150181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial activity of new beta-lactams and aminoglycosides in vitro under conditions of anaerobiosis].
    Bol'shakov LV; Bogomolova NS; Shenderov BA
    Antibiot Khimioter; 1989 Jul; 34(7):534-9. PubMed ID: 2818086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
    J Antimicrob Chemother; 2002 Sep; 50(3):411-20. PubMed ID: 12205068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefoxitin in the treatment of aerobic and anaerobic infections. Prospective correlation of in vitro susceptibility methods with clinical outcome.
    Goldstein EJ; Citron DM; Cole RE; Rangel DM; Seid AS; Ostovari MO
    Hosp Pract (Off Ed); 1990 Oct; 25 Suppl 4():38-45. PubMed ID: 2120272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.
    Burkhardt O; Derendorf H; Welte T
    Expert Opin Pharmacother; 2007 Feb; 8(2):237-56. PubMed ID: 17257093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez H
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1136-40. PubMed ID: 11897608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ertapenem: a review of its use in the treatment of bacterial infections.
    Keating GM; Perry CM
    Drugs; 2005; 65(15):2151-78. PubMed ID: 16225376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua.
    Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE
    Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sensitivity tests to antibiotics for aerobes and anaerobes in clinical practice].
    Brenciaglia MI; Rivanera D; Lilli D; Filadoro F
    Nuovi Ann Ig Microbiol; 1982; 33(2-3):349-74. PubMed ID: 7187036
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic implications of bacteriologic findings in mixed aerobic-anaerobic infections.
    Finegold SM; Wexler HM
    Antimicrob Agents Chemother; 1988 May; 32(5):611-6. PubMed ID: 3293522
    [No Abstract]   [Full Text] [Related]  

  • 19. Ertapenem: a review of its use in the management of bacterial infections.
    Curran M; Simpson D; Perry C
    Drugs; 2003; 63(17):1855-78. PubMed ID: 12921489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In vitro activity of ertapenem against clinical bacterial isolates in 69 Spanish medical centers (E-test study)].
    Gobernado M; Sanz-Rodríguez C; Villanueva R; Torroba L; Redondo E; González-Esteban J
    Rev Esp Quimioter; 2007 Dec; 20(4):395-408. PubMed ID: 18563213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.